NEW YORK STATE MEDICAID PROGRAM

LABORATORY

PROCEDURE CODES

Table of Contents

GENERAL INFORMATION AND RULES	2
ORGAN OR DISEASE ORIENTED PANELS	- 11
DRUG TESTING	- 12
THERAPEUTIC DRUG ASSAYS	- 12
EVOCATIVE/SUPPRESSION TESTING	13
URINALYSIS	- 14
CHEMISTRY	- 14
HEMATOLOGY AND COAGULATION	- 24
IMMUNOLOGY	- 26
TRANSFUSION MEDICINE	30
MICROBIOLOGY	30
CYTOPATHOLOGY	34
CYTOGENETIC STUDIES	- 35
SURGICAL PATHOLOGY	36
OTHER PROCEDURES	- 38

GENERAL INFORMATION AND RULES

- The fees in the Laboratory Fee Schedule apply to clinical laboratory tests selected from <u>Physician's Current Procedural Terminology (CPT)</u>, Fourth Edition, 2005 revision or the <u>Healthcare Common Procedure Coding System</u> (HCPCS), Seventeenth Edition, 2005. Reimbursement is limited to indicated uses of procedures that are FDA approved for in vitro diagnostic use or, are recognized as generally acceptable by the New York State Department of Health.
- 2. The fees include the services of all licensed professionals required by certification in the performance of the test.
- 3. The fees include all costs related to specimen testing, including collection, storage and transport of specimens, in addition to performance and reporting of results. Unreported instrument controls are not separately reimbursable. "By Report" (BR), as indicated in the Fee Schedule, reimbursement requires a statement indicating the need for the service, the type of test performed, the number and source of the specimen(s) and documentation, of the laboratory's usual and customary charge to the general public for the service.
- 4. The fees are for **quantitative** analyses, unless otherwise specified. Mathematical calculations (e.g., calculation of A/G ratio, ionized calcium, free thyroxine index (T-7) or osmolality) are not reimbursable.
- 5A. Therapeutic drug monitoring is reimbursable when quantitative determination of blood concentration is clinically relevant as a part of a regimen designed to attain and sustain therapeutic effect by maintenance of blood level within a defined range. The intensity and probability of therapeutic or toxic effect must quantitatively correlate with blood concentration. In addition, one or more of the following criteria must be satisfied: (1) there is a narrow range between those concentrations giving the desired response and those producing toxicity, (2) readily assessed alternative endpoints(e.g., prothrombin time for oral anticoagulants) are lacking or (3) there is large interindividual variability in the absorption and disposition of the drug.

Therapeutic monitoring is a covered service only when performed on specimens of **blood**. Use the drug specific codes 80150-80202, 82980 or 83858. Codes 80299 or 82205 are to be used only for drugs, which meet the criteria for therapeutic monitoring, outlined above and are not listed by individual code. Codes 80299 and 82205 are billable "**By Report**" and the drug(s) must be specified in the procedure description field on the Claim Form.

Peak and trough (or predose and postdose) analyses, when clinically indicated (e.g., aminoglycosides), are reimbursable as two procedures.

- 5B. The fee for code 80100 or 80101 covers screening of one specimen for any drugs including but not limited to alcohol, amphetamines, barbiturates, benzodiazepines, cocaine and metabolites, methadone, methagualones, opiates, phencyclidines, phenothiazine, propoxyphenes, quinine, tetrahydrocannaboinoids (marijuana) and tricyclic antidepressants. Screening by a broad-spectrum chromatographic procedure, which detects multiple drug classes, should be billed using code 80100. Each step in the sequential development of a chromatograph is NOT considered a separate procedure. When an analytical condition, e.g., column temperature or flow rate, is changed such that additional controls must be run, subsequent analysis of the same specimen for additional drug(s) is considered a separate procedure for billing purposes. Screening by immunoassay or a chromatographic method, which detects a single drug or drug class should be billed, per procedure, using code 80101. Confirmation of presumptive positives (or presumptive negatives for compliance monitoring) MUST be by methodology of differing chemical and physical principle from that used in the initial screen. Code 80102 is billable per confirmatory procedure, regardless of analytical method. Quantitation of detected drugs is not reimbursable. Code 82205 is for therapeutic monitoring only.
- 6A. Certain laboratory procedures are often performed, either manually or on automated equipment, in combination with each other. For purposes of reimbursement, when a code defines a specific combination of procedures performed on a date of service, it is appropriate to utilize that unique code.
- 6B. When procedures for Vitamin B12 (82607) and Folate (82746 or 82747) are performed in combination, the maximum reimbursable fee for code 82746 or 82747 is \$6.25. When a procedure for Ferritin (82728) is performed in combination with Vitamin B12 or Folate, or any of the Organ or Disease Oriented Panels (80048-80076), or any of the individual chemistry analyte codes listed in the fee schedule (see Rule 6A), the maximum reimbursable fee for 82728 is \$5.70.
- 6C. When two or more Hepatitis B tests are performed in combination, reimbursement will be reduced by 50% for each test after the first. See also Rule 16. When Hepatitis A, C or D tests (codes 86692, 86708, 86709, 86803 or 87380) are performed in combination with each other or with any Hepatitis B test, the maximum reimbursable fee per Hepatitis A, C or D test is \$5.00. When multiple procedures for antigen or antibody to two or more infectious agents (codes 86602-86689 and 86698-86703 or 86710-86793) are performed in combination, reimbursement is limited to the greater fee plus 50% of the lesser fee(s). The fee for code 86701 Antibody HIV-1 includes reimbursement for up to three screen assays of a single specimen. Use code 87390 for P24 HIV antigen.
- 7A. For purposes of reimbursement based on the Laboratory Fee Schedule, a complete blood count (CBC) includes a hematocrit, hemoglobin determination, RBC count, RBC indices, WBC count and a platelet count. See code 85027. For a CBC with an automated differential WBC count, use code 85025. **Code 85060 requires interpretation by physician and written report.**

- 7B. Codes for CBC individual components (85013, 85014, 85018, 85048 and 85049) may not be billed in conjunction with procedure codes including a CBC (85025 and 85027). The code for automated differential WBC count (85004) may not be billed in conjunction with codes 85025 and 85027.
- 8. For purposes of reimbursement, codes 86850-86905 represent examples of procedures considered to be integral parts of outpatient transfusion and hemodialysis services. No separate reimbursement will be allowed.
- 9. For **pregnancy detection** and where the reported test result is qualitative or semi-quantitative, use code 81025 or 84703. Code 84702 is reimbursable for a quantitative HCG value reported for a diagnostic use (e.g., monitoring post surgical growth of germ cell neoplasm where quantitative HCG is relative to growth). Code 84702 is not reimbursable for a routine screen for pregnancy.
- 10. Appropriate billing of antibody and antigen procedures is as follows:
 - A. For antibody or antigen as specific markers of infectious disease, use the most specific code corresponding to the organism name (e.g., 86618 Antibody; Borrelia burgdorferi) <u>or</u> the disease name (e.g., 87340 Hepatitis B surface antigen).
 - B. For an infectious agent antibody or antigen not listed by name, use the "By Report" code for the type of organism (e.g., 86609 Antibody; bacterium not elsewhere specified or the analytical method, e.g. 87299 Infectious agent antigen detection by immunofluorescent technique; not otherwise specified, each organism). Document the name of the organism, and, if applicable, the immunoglobulin subclass(es), on the Claim Form (See Rule 3).
 - C. For antibody other than to infectious agent(s) (e.g., autoantibodies) use the most specific code corresponding to the analyte (e.g., 86376 Microsomal antibody (e.g. thyroid or liver-kidney, each)).
 - D. For non-infectious agent antibody or antigen NOT listed by analyte, use the **most** specific code for the method used (e.g., 86255 Fluorescent **noninfectious** agent antibody; screen each antibody); when billing "**By Report**", the name of the analyte must be documented on the Claim Form (See Rule 3).
 - E. Multiple tests to detect (1) antibodies to organisms/analytes classified more precisely than the specificity allowed by available codes, (2) antibodies in paired specimens (acute vs. convalescent), or (3) antibodies of different immunoglobulin subclasses, are reimbursable as separate procedures; multiple units of a code (e.g., two units of 86658 for Coxsackie A and B species of enterovirus) may be claimed when analyses yield separately reported results for each subclassification, specimen or Ig subclass.

- 11. Organ or Disease Orientated Panel codes. Effective July 1, 2000, the panel codes 80047, 80048, 80051, 80053, 80061, 80069 and 80076 should be used to bill designated combinations of tests regardless of whether the tests are ordered and/or performed individually, as a panel, or as multiple panels at different times. If 2 or more panel codes with overlapping component tests, (i.e., 80047, 80048, 80051, 80053, 80076) are billed, the lab is not entitled to reimbursement for the duplicate tests. If one or more of the codes for chemistry tests where this rule applies are billed in combination with another and/or a panel code, total payment due for those chemistry tests is limited as follows: up to 2=\$5.03, 3-6=\$6.04, 7-9=\$7.25, 10-12=\$9.09, 13-16=\$10.00, 17-18=\$11.00, 19 or more=\$12.00.
- 12. Cytogenetic studies codes 88245, 88267 and 88269 must be billed in combination with code 88280 to report a 2-karyotype chromosome analysis as described in the quality control standards for cytogenetic licensure.
- 13. Reimbursement for immunoelectrophoresis includes payment for the electrophoretic separation and quantitation. Therefore, no separate reimbursement for code 84165 will be allowed when code(s) 86320-86325 are billed.
- 14. The molecular diagnostics codes (83890-83913) are reimbursable for DNA-based genetic testing performed as (1) a family study of up to six individuals (up to a maximum of six probes or primer pairs per individual) to determine the genetic carrier/disease status of an individual patient or a fetus as part of a comprehensive program of genetic counseling and where indicated by familial medical history or adjunctive prenatal testing OR (2) an individual study by diagnostic deletion analysis of a patient affected by a genetic disorder. DNA-based testing defined under State licensure as investigational for a certain disease is not reimbursable. Codes 83890-83913 are not reimbursable for non-genetic applications such as microbial detection or quantification, or testing for acquired changes in genetic material (e.g., T or B cell markers, immunoglobulin heavy or light chain rearrangements associated with malignancy). The listed fee for code 83912 is for interpretation and report of a single specimen, e.g., a carrier study. When using code 83912 to claim reimbursement for pedigree or linkage analysis, submit a report according to "By Report" instructions in Rule 3.
- 15. Code 82105, 82106, 82378, 83950, 83951, 84066, 84153, 84154, 84702 or 86316 is reimbursable for an **oncofetal antigen** (tumor marker) procedure used as an adjunctive test with other accepted tests in monitoring for tumor growth recurrence in a patient who has had a tumor irradiated or surgically removed. Codes 82105 and 82106 are also reimbursable for alpha-fetoprotein testing used for prenatal (nondiagnostic) gestational age dependent screening for neural tube defects. Code 86316 for immunoassay for a tumor antigen not elsewhere specified, e.g., CA 50, is billable "By Report". When a procedure for (CEA) carcinoembryonic antigen (82378) is performed in combination with Comprehensive Metabolic Panel (code 80053) the maximum reimbursable fee for code 82378 is \$8.00. A test for an oncofetal antigen (tumor marker) is reimbursable for diagnostic purposes only when used in accordance with the FDA approval criteria for its use.

continued on next page

When 84153 and 84152 or 84154 are billed in combination, the maximum fee for 84152 or 84154 is \$21.35.

- 16. Claims for reimbursement for procedures generally considered to be follow-up testing must be supported by reporting a specific (presumptive) diagnosis which considers the results of the initial test(s) as well as the patient's history, symptoms, etc. The ordering practitioner must supply such diagnosis, or reason for the patient encounter, to the laboratory. For example:
 - A. Code 82172 is reimbursable when performed for diagnostic purposes for a patient with documented elevated total cholesterol (>240 mg/dl) and an abnormally low HDL cholesterol level (< 35 mg/dl) and/or documented family history of coronary artery disease (CAD). A test for apolipoprotein(s) is **not** reimbursable when used as a **screening** procedure for CAD risk assessment.
 - B. Thyroid function tests other than "screen" tests for clinically suspected thyroid dysfunctions are reimbursable only when indicated for differential diagnosis, to resolve disagreement with documented clinical impressions, to resolve equivocal results or to monitor therapeutic regimens of diagnosed thyroid-dysfunctional patients. For purposes of this rule, a "screen" test is <u>either</u> total thyroxine (84436) <u>or</u> free thyroxine index (84436 + 84479) <u>or</u> sensitive-TSH (84443).
 - C. Serologic markers that are clinically indicated for staging, management or prognosis of viral hepatitis B are reimbursable only when it is determined by initial diagnostic testing that the patient has type B hepatitis.
- 17. The fee for presumptive identification of microbial culture isolates includes reimbursement for all procedures used to presumptively identify the organism, including stains. When definitive identification is medically necessary and additional methods are used for definitive identification, (e.g., molecular methods) use code 87076 or 87077, as applicable, in addition to the appropriate code for isolation (87040 87075).
- 18. Lymphocyte evaluation by immunophenotyping is reimbursable for analysis of lymphocyte subpopulations for monitoring of disease activity and therapeutic response in, for example, immunodeficiency or autoimmune disease, or cancer. Only those antibodies or "markers" FDA-approved or cleared and/or approved by the Department are reimbursable as follows:
 - A. Bill 1 unit of code 86360 when the lab performs an "abbreviated lymphocyte" analysis panel* by 2-color flow cytometric analysis or any acceptable tube combination out of the possible four analysis tubes by 3 or 4-color flow cytometric analysis, and reports absolute CD4 counts with CD8 counts;
 - B. Bill 2 units of code 86360 when the lab performs a "full lymphocyte" analysis panel* by 2, 3 or 4-color flow cytometric analysis and reports absolute CD4 counts with CD8 counts. Codes 86355, 86357, 86359, 88184, 88185 and 88187 through 88189 are not reimbursable for a 'full lymphocyte' analysis panel when only performing absolute CD4 counts with CD8 counts;

- C. Bill 1 unit of code 86361 when the lab performs lymphocyte subpopulation counts by a method other than flow cytometry or microscopy, and reports only absolute CD4 counts with or without CD8 counts;
- D. Bill 1 unit of one or more of the codes 86355, 86357, 86359, 86367, 88184 and whenever appropriate, 1 or more units of 88185, when the lab performs flow cytometric testing using multiple markers (e.g. lymphoma/leukemia testing). When CD4/CD8 analysis is included, 1 unit of 86360 should be billed in addition, and when CD4 analysis is included (without CD8), bill 1 unit of 86361 in addition. Codes 86360 and 86361 may not be billed for the same date of service. 88184 and 88185 should be used for unlisted markers, including markers used to draw gates, set cursors and monitor variability. Bill 1 unit of the appropriate interpretation code (88187 through 88189) based on the total number of markers performed;
- E. Bill code 88346 or 88347 when the lab performs microscopic or other non-flow cytometric subset analysis using tagged antibody(ies); bill 1 unit of code 88346 or 88347 per marker.

* "Abbreviated lymphocyte" and "full lymphocyte" panels are as defined by the New York State Cellular Immunology Proficiency Testing Program.

- 19. Code **86341 Islet cell antibody** is reimbursable when used to differentiate type I from type II diabetes in patients with equivocal clinical presentation. It is <u>not</u> reimbursable when used as a predicator of disease, e.g., in first-degree relatives of persons with diabetes mellitus.
- 20. Code **87536 HIV-1 quantitation** is reimbursable when used in patient management to predict clinical outcomes, to predict risk of disease progression, and/or to provide information for a decision to initiate antiretroviral drug therapy or to change treatment regimes. This test is allowed as clinically indicated up to a <u>maximum</u> of six per year.
- 21. HIV genotypic/phenotypic drug resistance testing and phenotypic prediction using genotypic comparison to known databases is a covered service when clinically indicated. Medicaid will reimburse each test (87900, 87901, 87903, 87904) up to a maximum of three times in a 365-day period across all providers or any combination of 87901 and 87903 up to a maximum of four times in a 365-day period across all providers.

Effective for dates of service on and after **April 1, 2002**, code 87903 reimburses \$675.29 for resistance determinations of up to 10 antiviral drugs. Code 87904 should be billed in addition to 87903 to claim reimbursement for additional drug resistance determinations, using one unit for **each (1) additional drug**.

When codes 87901 and 87903 are billed with the same date of service, the maximum reimbursable fee for the combination of 87901 and 87903 is \$925.29, i.e., \$100 less than the additive maximum fees for the codes.

- 22. For instrumented screening of PAP smears (codes 88174 and 88175), the following definitions apply:
 - A. For code 88174, "screening by automated system" means primary examination by a slide profiling system without human review and primary examination by human review of all fields of vision selected by a locations-guidance system, with or without quality assurance manual or automated re-screening.
 - B. For code 88175, "screening by automated systems and manual rescreening" means primary examination by human review of all or some fields of vision selected by a location guidance system, and, in addition, full slide review (e.g., AutoScan mode engaged), with or without quality assurance manual or automated rescreening.
- 23. Effective September 1, 2004, travel expenses associated with in-home phlebotomy services, i.e., blood draws, is reimbursable using code P9604. The recipient must be eligible for in-home phlebotomy as documented by a qualified ordering practitioner and defined below.

A recipient is eligible for in-home phlebotomy if:

- The recipient is homebound, which means he or she has a condition due to illness or injury that precludes access to routine medical services outside of his/her residence without special arrangements for transportation, i.e., ambulance, ambulette, and taxi with assistance in areas where public transportation is unavailable; or has a condition that makes leaving the residence medically contraindicated; *and*,
- 2. The recipient is participating in a Medicaid-covered home care program or is currently receiving a Medicaid-covered home care service, i.e., personal care services, certified home health agency (CHHA) services, consumerdirected personal assistance services, or the Long Term Home Health Care Program (LTHHCP).

Travel expenses are NOT a covered service if they are solely to:

- 1. Draw blood from patients in a skilled nursing facility;
- 2. Draw blood from a recipient who receives medical services in his or her residence from a professional whose scope of practice authorizes the drawing of blood; or,
- 3. Pick-up and transport a specimen collected by a home health care provider or anyone other than a laboratory representative.

The laboratory is entitled to only one fee for one-way or round-trip travel to a single address, regardless of the number of specimens collected or the number of recipients drawn at that location. There is a limit of 12 claims per recipient per year for in-home phlebotomy service; this allows for 12 round-trips or 12 one-way trips, or any combination of no more than 12 round or one-way trips. The number of specimens collected per trip must be documented.

continued on next page

To calculate the appropriate reimbursement amount for claiming travel to and from in-home phlebotomy services, multiply the number of trips or stops (including the return trip to the laboratory) by the fee and divide this amount by the number of patients seen. The laboratory will pro-rate when the claim is submitted based on the number of patients seen on that trip. The "same address" is defined as a building or complex with the same entrance and egress off of a public road, such as an apartment complex.

Rules for billing, including pro-rating for multiple recipients:

1. One recipient at one site: A laboratory representative travels from the laboratory to the home of one recipient and returns to the laboratory without making any other stops. The trip out and back is paid as a round-trip. The laboratory should submit a single line claim for **\$18.70** ($2 \times$ \$9.35 = \$18.70).

2. One recipient at each of multiple sites: A laboratory representative travels in a circuit from the laboratory to the home of each of six recipients and returns to the laboratory. Each segment is paid as a one-way trip at a flat rate of \$9.35. The laboratory is entitled to a total of 65.45 (7 x 9.35 = 65.45) but, since a separate claim must be submitted for each recipient, 65.45 must be divided by the number of recipients, which is six. Each of the six recipient claims would be submitted for **\$10.91**.

3. Multiple recipients at a single address: A laboratory representative travels from the laboratory to an apartment complex, draws blood from six recipients and returns to the laboratory. The laboratory is entitled to one round trip fee of \$18.70, but, since a separate claim must be submitted for each recipient, the \$18.70 must be divided by the number of recipients, which is six. Each of the six recipients' claims would be submitted for **\$3.12**.

4. Multiple recipients at one address + one recipient at each of several additional sites: A laboratory representative travels from the laboratory to an apartment complex and draws blood from three recipients; he then continues his circuit to three separate residences, and draws blood from one recipient at each, and returns to the laboratory. The laboratory should bill as follows:

The laboratory is entitled to \$9.35 for the trip segment from the laboratory to the apartment complex;

For each of the three recipients drawn at separate addresses, the laboratory is entitled to \$9.35 trip segment. The laboratory is also entitled to \$9.35 for the return to the laboratory. The total would be four times \$9.35, or \$37.40.

The total number of stops are 5 (one stop from the laboratory to the apartment complex, stops at three recipients' homes and the return trip to the laboratory). The laboratory is entitled to a total of \$46.75 (5 x 9.35 = 46.75), but since a separate claim must be submitted for each recipient, \$46.75 must be divided by the number of recipients which is six. Each of the six recipient's claims would be submitted for \$7.79.

- 24. The Medicaid definition for "date of service" for laboratory providers is the date of specimen collection. For laboratory tests that use a specimen taken from storage, the date of service is the date the specimen was removed from storage.
- 25. NCCI Modifiers:

Note- NCCI associated modifiers are recognized for NCCI code pairs/related edits. For additional information please refer to the CMS website: <u>http://www.cms.hhs.gov/NationalCorrectCodInitEd/</u>

- -59 Distinct procedural service
- -91 Repeat clinical diagnostic laboratory test

DESCRIPTION

ORGAN OR DISEASE ORIENTED PANELS (see Rule 11)

80047 Basic metabolic panel (Calcium, ionized) This panel must include the following: Calcium. ionized (82330). Carbon dioxide (82374), Chloride (82435), Creatinine (82565), Glucose (82947), Potassium (84132), Sodium (84295), Urea Nitrogen (BUN) (84520) 80048 Basic metabolic panel (Calcium, total) This panel must include the following: Calcium, total (82310), Carbon dioxide (82374), Chloride (82435), Creatinine (82565), Glucose (82947), Potassium (84132), Sodium (84295), Urea Nitrogen (BUN) (84520) 80051 Electrolyte panel This panel must include the following: Carbon dioxide (82374), Chloride (82435), Potassium (84132), Sodium (84295) 80053 Comprehensive metabolic panel This panel must include the following: Albumin (82040), Bilirubin, total (82247), Calcium, total (82310), Carbon dioxide (bicarbonate) (82374), Chloride (82435), Creatinine (82565), Glucose (82947), Phosphatase, alkaline (84075), Potassium (84132), Protein, total (84155), Sodium (84295), Transferase, alanine amino (ALT) (SGPT) (84460), Transferase, aspartate amino (AST) (SGOT) (84450), Urea Nitrogen (BUN) (84520) 80061 Lipid panel This panel must include the following: Cholesterol, serum, total (82465), Lipoprotein, direct measurement, high density cholesterol (HDL cholesterol) (83718), Triglycerides (84478) 80069 Renal function panel This panel must include the following: Albumin (82040), Calcium, total (82310), Carbon dioxide (bicarbonate) (82374), Chloride (82435), Creatinine (82565), Glucose (82947), Phosphorus, inorganic (phosphate) (84100), Potassium (84132), Sodium (84295), Urea nitrogen (BUN) (84520) 80076 Hepatic function panel This panel must include the following:

Albumin (82040), Bilirubin, total (82247), Bilirubin, direct (82248), Phosphatase, alkaline (84075), Protein, total (84155), Transferase, alanine amino (ALT) (SGPT) (84460), Transferase, aspartate amino (AST) (SGOT) (84450)

DESCRIPTION

DRUG TESTING

Qualitative screening tests are reimbursable per procedure, not method or analyte, using code 80100 or 80101. Use code 80102 for each procedure necessary for confirmation. See Rule 5B.

- 80100 Drug screen, qualitative; multiple drug classes chromatographic method, each procedure
- 80101 single drug class method (e.g., immunoassay, enzyme assay), each drug class
- 80102 Drug confirmation, each procedure

THERAPEUTIC DRUG ASSAYS

Quantitative therapeutic drug monitoring is reimbursable only when performed on specimens of **blood** as outlined in Rule 5A.

(For barbiturates not specifically listed by name, use 82205)

80150 Amikacin 80152 Amitriptyline 80156 Carbamazepine; total 80157 free 80158 Cyclosporine 80160 Desipramine 80162 Digoxin 80164 Dipropylacetic acid (valproic acid) 80166 Doxepin 80168 Ethosuximide 80170 Gentamicin (For glutethimide, use 82980) 80173 Haloperidol 80174 Imipramine 80178 Lithium (For methsuximide, use 83858) 80182 Nortriptyline Phenobarbital 80184 80185 Phenytoin; total free 80186 80188 Primidone 80194 Quinidine 80195 Sirolimus 80196 Salicvlate 80197 Tacrolimus 80198 Theophylline

DESCRIPTION

80200 Tobramycin

80202 Vancomycin

80299 Quantitation of drug, not elsewhere specified (see Rule 5A)

EVOCATIVE/SUPPRESSION TESTING

The following tests involve the administration of evocative or suppressive agents and the baseline and subsequent measurement of their effects on chemical constituents. The costs of the evocative or suppressive agents are not included in the fee, with the exception of oral glucose for codes 80430 and 82950 – 82953. Reference to a particular analyte in the code description (e.g., cortisol x 2) indicates the minimum number of times that particular analysis must be performed in order to claim reimbursement for the test. When multiple evocative or suppressive tests are performed in combination reimbursement is limited to the greater fee plus 50% of the lesser fee(s).

- 80400 ACTH stimulation panel; for adrenal insufficiency (cortisol x 2)
- for 21 hydroxylase deficiency (cortisol x 2 and 17 hydroxyprogesterone x 2)
- 80406 for 3 beta-hydroxydehydrogenase deficiency (cortisol x 2 and 17 hydroxypregnenolone x 2)
- 80410 Calcitonin stimulation panel (e.g., calcium, pentagastrin) (calcitonin x 3)
- 80414 Chorionic gonadotropin stimulation panel; testosterone response (testosterone x 2)
- 80415 estradiol response (estradiol x 2)
- 80416 Renal vein renin stimulation panel (e.g., captopril) (renin x 6)

(For a single measurement of blood cortisol after administration of dexamethasone, use 82533)

80420 Dexamethasone suppression panel, 48 hour (free cortisol/urine x 2 and cortisol x 2)

(For gastrin-secretin stimulation test, use 82938)

(For glucose tolerance test, use 82951 +/-82952)

- 80426 Gonadotropin releasing hormone stimulation panel (follicle stimulating hormone (FSH) x 4 and luteinizing hormone (LH) x 4)
- 80428 Growth hormone stimulation panel (e.g., arginine infusion, I-dopa administration) (human growth hormone (HGH) x 4)
- 80430 Growth hormone suppression panel (includes glucose) (glucose x 3 and human growth hormone (HGH) x 4)
- 80432 Insulin-induced C-peptide suppression panel (insulin x 1 and C-peptide x 5 and glucose x 5)
- 80436 Metyrapone panel (cortisol x 2 and 11-deoxycortisol x 2)
- 80438 Thyrotropin releasing hormone (TRH) stimulation panel; one hour (thyroid stimulating hormone (TSH) x 3)

(For tolbutamide tolerance test, use 82953) (For xylose tolerance test, use 84620)

DESCRIPTION

URINALYSIS

- 81000 Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, ph, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, with microscopy
- automated, with microscopy 81001
- 81002 non-automated, without microscopy
- 81003 automated, without microscopy
- Urinalysis; bacteriuria screen, except by culture or dipstick 81007
- microscopic only 81015
- Urine pregnancy test, by visual color comparison methods 81025

(For microalbumin, use 82043, 82044)

CHEMISTRY

- 82009 Acetone or other ketone bodies, serum; qualitative
- 82013 Acetvlcholinesterase
- 82016 Acylcarnitines; qualitative, each specimen
- quantitative, each specimen 82017

(For carnitine, see 82379)

- 82024 Adrenocorticotropic hormone (ACTH)
- 82040 Albumin; serum, plasma or whole blood (see Rule 11)
- 82042 urine or other source, quantitative, each specimen (see Rule 11)
- urine, microalbumin, quantitative (see Rule 11) 82043
- 82044 urine, microalbumin, semiguantitative (e.g., reagent strip assay) (see Rule 11)
- ischemia modified 82045
- 82088 Aldosterone
- 82103 Alpha-1-antitrypsin; total
- 82104 phenotype
- Alpha-fetoprotein (AFP); serum 82105
- amniotic fluid 82106

(For alpha-2-macroglobulin, see 86329)

- 82107 AFP-L3 fraction isoform and total AFP (including ratio)
- 82108 Aluminum
- Amines, vaginal fluid, gualitative 82120
- Amino acids; single, qualitative, each specimen (not elsewhere specified) 82127 multiple, qualitative, each specimen (not elsewhere specified) 82128
- single, quantitative, each specimen, (not elsewhere specified) 82131
- 82136 Amino acids, 2 to 5 amino acids, quantitative, each specimen
- 82139 Amino acids, 6 or more amino acids, quantitative, each specimen
- Ammonia (blood) 82140

CODE DESCRIPTION

- 82143 Amniotic fluid scan (spectrophotometric)
- 82150 Amylase (see Rule 11)
- 82154 Androstanediol glucuronide
- 82157 Androstenedione

(For androsterone, see ketogenic steroids 83593)

- 82172 Apolipoprotein, each (see Rule 16)
- 82175 Arsenic
- 82180 Ascorbic acid (Vitamin C), blood
- 82205 Barbiturates, not elsewhere specified **(therapeutic monitoring only)** (see Rule 5)
- 82232 Beta-2 microglobulin
- 82239 Bile acids; total
- 82240 cholylglycine
- 82247 Bilirubin; total (see Rule 11)
- direct (see Rule 11)
- 82261 Biotinidase, each specimen
- 82270 Blood, occult, by peroxidase activity (e.g., guaiac), qualitative; feces, consecutive collected specimens with single determination, for colorectal neoplasm screening (e.g., patient was provided three cards or single triple card for consecutive collection)
- 82274 Blood, occult, by fecal hemoglobin determination by immunoassay, qualitative, feces, 1-3 simultaneous determinations
- 82300 Cadmium
- 82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed
- 82308 Calcitonin
- 82310 Calcium; total (see Rule 11)
- ionized (see Rule 11)
- urine quantitative, timed specimen (see Rule 11)
- 82355 Calculus; qualitative analysis
- 82360 quantitative analysis, chemical
- 82365 infrared spectroscopy
- 82370 x-ray diffraction
- 82373 Carbohydrate deficient transferrin
- 82374 Carbon dioxide (bicarbonate) (see Rule 11)
- 82375 Carboxyhemoglobin; quantitative
- 82378 Carcinoembryonic antigen (CEA) (see Rule 15)
- 82379 Carnitine (total and free), quantitative, each specimen
- 82382 Catecholamines; total urine
- 82383 blood
- 82384 fractionated
- 82390 Ceruloplasmin
- 82435 Chloride; blood (see Rule 11)
- 82436 urine (see Rule 11)

<u>CODE</u>

DESCRIPTION

00400	other course (cos Dula 11)
82438	other source (see Rule 11)
	(For sweat collection by iontophoresis, use 89230)
82465	Cholesterol, serum or whole blood, total (see Rule 11)
	(For high density lipoprotein (HDL), see 83718)
82480	Cholinesterase; serum
82495	Chromium
82507	Citrate
82523	Collagen cross links, any method
82525	Copper Corticoly free
82530	Cortisol; free
82533 82550	total Creatine kinase (CK),(CPK); total (see Rule 11)
82550	isoenzymes
82553	MB fraction only
82565	Creatinine; blood (see Rule 11)
82570	other source (see Rule 11)
82575	clearance (see Rule 11)
82595	Cryoglobulin, qualitative or semi-quantitative (e.g., cryocrit)
82607	Cyanocobalamin (Vitamin B-12); (see Rule 6B)
82608	unsaturated binding capacity
82615	Cystine and homocystine, urine, qualitative
82626	Dehydroepiandrosterone (DHEA)
82627	Dehydroepiandrosterone-sulfate (DHEA-S)
82634	Deoxycortisol, 11-
82656	Elastase, pancreatic (EL-1), fecal, qualitative or semi-quantitative
82668	Erythropoietin
82670	Estradiol
82672	0
82677	
82679	Estrone
	(For etiocholanolone, see ketogenic steroids 83593)
82705	Fat or lipids, feces; qualitative
82710	quantitative
82726	Very long chain fatty acids
82728	Ferritin
82731	Fetal fibronectin, cervicovaginal secretions, semi-quantitative
82746	Folic acid; serum (see Rule 6B)
82747	RBC (see Rule 6B)
	(For fructocoming, use 82085)

(For fructosamine, use 82985)

DESCRIPTION

- 82759 Galactokinase, RBC
- 82760 Galactose
- 82775 Galactose-1-phosphate uridyl transferase; quantitative
- 82784 Gammaglobulin (immunoglobulin); IgA, IgD, IgG, IgM, each
- 82785 IgE
- immunoglobulin subclasses (eg, IgG1, 2, 3 or 4), each
- 82803 Gases, blood, any combination of (two or more) pH, pC02, p02, C02, HC03 (including calculated 02 saturation);
- 82805 with 02 saturation, by direct measurement, except pulse oximetry
- 82810 Gases, blood, O2 saturation only, by direct measurement, except pulse oximetry
- 82820 Hemoglobin-oxygen affinity (pO2 for 50% hemoglobin saturation with oxygen)
- 82938 Gastrin after secretin stimulation
- 82941 Gastrin
- 82943 Glucagon
- 82945 Glucose, body fluid, other than blood (see Rule 11)
- 82947 Glucose; quantitative, blood (except reagent strip) (see Rule 11)
- blood, reagent strip
- 82950 post glucose dose (includes glucose)
- tolerance test (GTT), three specimens (includes glucose)
- tolerance test, each additional beyond three specimens
- 82953 tolbutamide tolerance test (glucose x 7 and insulin x 7) (includes glucose, for more information see Evocative/Suppression Testing Section)
- 82955 Glucose-6-phosphate dehydrogenase (G6PD); quantitative
- 82960 screen
- 82963 Glucosidase, beta
- 82965 Glutamate dehydrogenase
- 82977 Glutamyltransferase, gamma (GGT) (see Rule 11)
- 82980 Glutethimide
- 82985 Glycated protein

(For gonadotropin, chorionic, see 81025, 84702, 84703)

- 83001 Gonadotropin; follicle stimulating hormone (FSH)
- 83002 luteinizing hormone (LH)
- 83003 Growth hormone, human (HGH) (somatotropin)

(For multiple measurements of growth hormone in stimulation/suppression tests, see 80428 – 80430)

- 83009 Helicobacter pylori, blood test analysis for urease activity, non-radioactive isotope (e.g., C-13) (includes kit)
- 83010 Haptoglobin; quantitative
- 83013 Helicobacter pylori; breath test analysis for urease activity, non-radioactive isotope (includes kit)
- 83015 Heavy metal (arsenic, barium, beryllium, bismuth, antimony, mercury); screen

CODE DESCRIPTION

83020	Hemoglobin fractionation and quantitation; electrophoresis (e.g., A2, S, C, and/or F)
83021	chromatography (e.g., A2, S, C, and/or F)
83030	Hemoglobin; F (fetal), chemical
83036	glycosylated (A1C)
	(For fecal hemoglobin detection by immunoassay, use 82274)
83050	methemoglobin, quantitative
83051	plasma
83080	b-Hexosaminidase, each assay (Tay Sachs diagnostic/carrier testing)
83090	Homocystine
83150	Homovanillic acid (HVA)
83497	Hydroxyindolacetic acid, 5-(HIAA)
83498	Hydroxyprogesterone, 17-d
83500	Hydroxyproline; free
83505	total
83525	Insulin; total
83527	free
83540	Iron (see Rule 11)
83550	Iron binding capacity (see Rule 11)
83586	Ketosteroids, 17- (17-KS); total
83593	fractionation
83605	Lactate (lactic acid)
83615	Lactate dehydrogenase (LD), (LDH); (see Rule 11)
83625	isoenzymes, separation and quantitation
83630	Lactoferrin, fecal; qualitative
83631	quantitative
83655	Lead
83661	Fetal lung maturity assessment; lecithin sphingomyelin (L/S) ratio
83662	foam stability test
83663	fluorescence polarization
83664	lamellar body density
83690	Lipase
83718	Lipoprotein, direct measurement; high density cholesterol (HDL cholesterol)
00707	(see Rule 11)
83727	Luteinizing releasing factor (LRH)
83735	Magnesium (see Rule 11)
83785	Manganese
83825	Mercury, quantitative
83835	Metanephrines
83858	Methsuximide
83864 83866	Mucopolysaccharides, acid; quantitative screen
83876	Myeloperoxidase (MPO)
00070	

<u>CODE</u> <u>DE</u>

DESCRIPTION

83880	Natriuretic peptide
	(For coding guidelines for molecular diagnostic services, 83890-83913, see Rule 14)
83890	Molecular diagnostics; molecular isolation or extraction, each nucleic acid type (ie, DNA or RNA)
83891	isolation or extraction of highly purified nucleic acid, each nucleic acid type (ie, DNA or RNA)
83892	enzymatic digestion, each enzyme treatment
83893	dot/slot blot production, each nucleic acid preparation
83894	separation by gel electrophoresis (eg, agarose, polyacrylamide), each nucleic acid preparation
83896	nucleic acid probe, each
83897	nucleic acid transfer (eg, Southern, Northern), each nucleic acid preparation
83898	amplification, target, each nucleic acid sequence
83900	amplification, target, multiplex, first two nucleic acid sequences
83901	amplification, target, multiplex, each additional nucleic acid sequence
	beyond 2
	(List separately in addition to primary procedure) (see Rule 14)
83902	reverse transcription
83903	mutation scanning, by physical properties (e.g., single strand
	conformational polymorphisms (SSCP), heteroduplex, denaturing gradient gel electrophoresis (DGGE), (RNA'ase A), single segment, each
83904	mutation identification by sequencing, single segment, each segment
83905	mutation identification by allele specific transcription, single segment, each segment
83906	mutation identification by allele specific translation, single segment, each segment
83907	lysis of cells prior to nucleic acid extraction (eg, stool specimens, paraffin embedded tissue), each specimen
83908	amplification, signal, each nucleic acid sequence
	(For multiplex amplification, see 83900, 83901)
83909	separation and identification by high resolution technique (eg, capillary electrophoresis), each nucleic acid preparation
83912	interpretation and report (see Rule 14)
83913	RNA stabilization
83914	Mutation identification by enzymatic ligation or primer extension, single segment,
	each segment (e.g., oligonucleotide ligation assay (OLA), single base chain extension (SBCE), or allele-specific primer extension (ASPE))
S3713	KRAS mutation analysis testing
S3818	Complete gene sequence analysis; BRCA 1 gene
S3819	BRCA 2 gene

S3819 BRCA 2 gene

DESCRIPTION

S3820	Complete BRCA1 and BRCA2 gene sequence analysis for susceptibility to
	breast and ovarian cancer

- S3822 Single mutation analysis (in individual with a known BRCA1 or BRCA2 mutation in the family) for susceptibility to breast and ovarian cancer
- S3823 Three-mutation BRCA1 and BRCA2 analysis for susceptibility to breast and ovarian cancer in Ashkenazi individuals
- S3828 Complete gene sequence analysis; MLH1 gene
- S3829 Complete gene sequence analysis; MLH2 gene
- S3830 Complete MLH1 and MLH2 gene sequence analysis for hereditary nonpolyposis colorectal cancer (HNPCC) genetic testing
- S3831 Single-mutation analysis (in individual with a known MLH1 and MLH2 mutation in the family) for hereditary nonpolyposis colorectal cancer (HNPCC) genetic testing
- S3833 Complete APC gene sequence analysis for susceptibility to familial adenomatous polyposis (FAP) and attenuated FAP
- S3834 Single-mutation analysis (in individual with a known APC mutation in the family) for susceptibility to familial adenomatous polyposis (FAP) and attenuated FAP
- S3835 Complete gene sequence analysis for cystic fibrosis genetic testing
- S3840 DNA analysis for germline mutations of the RET proto-oncogene for susceptibility to multiple endocrine neoplasia type 2
- S3842 Genetic testing for Von Hippel-Lindau disease
- S3843 DNA analysis of the F5 gene for susceptibility to factor V Leiden thrombophilia
- S3844 DNA analysis of the connexin 26 gene (GJB2) for susceptibility to congenital, profound deafness
- S3845 Genetic testing for alpha-thalassemia
- S3846 Genetic testing for hemoglobin E beta-thalassemia
- S3847 Genetic testing for Tay-Sachs disease
- S3848 Genetic testing for Gaucher disease
- S3849 Genetic testing for Niemann-Pick disease
- S3850 Genetic testing for sickle cell anemia
- S3851 Genetic testing for Canavan disease
- S3852 DNA analysis for APOE epilson 4 allele for susceptibility to Alzheimer's disease
- S3853 Genetic testing for myotonic muscular dystrophy
- S3860 Genetic testing, comprehensive cardiac ion channel analysis, for variants in 5 major cardiac ion channel genes for individuals with high index of suspicion for familial long QT syndrome (LQTS) or related syndromes
- S3861 Genetic testing, sodium channel, voltage-gated, type V, alpha subunit (SCN5A) and variants for suspected Brugada Syndrome
- **S3865** Comprehensive gene sequence analysis for hypertrophic cardiomyopathy
- **S3866** Genetic analysis for a specific gene mutation for hypertrophic cardiomyopathy (HCM) in an individual with a known HCM mutation in the family
- **\$3870** Comparative genomic hybrization (CGH) microarray testing for developmental delay, autism spectrum disorder and/or mental retardation

<u>CODE</u>

DESCRIPTION

83918	Organic acids; total, quantitative, each specimen
83919	qualitative, each specimen
83921	Organic acid, single, quantitative
83930	Osmolality; blood (see Rule 4)
83935	urine (see Rule 4)
83945	Oxalate
83950	Oncoprotein; HER-2/neu (see Rule 15)
83951	des-gamma-carboxy-prothrombin (DCP)
83970	Parathormone (parathyroid hormone)
83993	Calprotectin, fecal
84030	Phenylalanine (PKU), blood
84060	Phosphatase, acid; total (see Rule 11)
84066	prostatic (see Rule 15)
84075 84078	Phosphatase, alkaline; (see Rule 11) heat stable (total not included) (see Rule 11)
84078 84080	isoenzymes
84080 84081	Phosphatidylglycerol (separate procedure)
84087	Phosphohexose isomerase
84100	Phosphorus inorganic (phosphate); (see Rule 11)
84105	urine (see Rule 11)
84106	Porphobilinogen, urine; qualitative
84110	quantitative
84119	Porphyrins, urine; qualitative
84120	quantitation and fractionation
84132	Potassium; serum, plasma or whole blood (see Rule 11)
84133	urine (see Rule 11)
	(For pregnancy test, use 81025 or 84703)
84134	Prealbumin
84140	Pregnenolone
84143	17-hydroxypregnenolone
84144	Progesterone
	(For 17-hydroxyprogesterone, use 83498)
84146	Prolactin
84152	Prostate specific antigen (PSA); complexed (direct measurement)
84153	total (see Rule 15)
84154	free (see Rule 15)
84155	Protein, total, except by refractometry; serum, plasma or whole blood (see Rule 11)
84156	urine (see Rule 11)
84157	other source (e.g., synovial fluid, cerebrospinal fluid) (see Rule 11)
84160	Protein, total, by refractometry, any source (see Rule 11)
84163	Pregnancy-associated plasma protein-A (PAPP-A)

84163 Pregnancy-associated plasma protein-A (PAPP-A)

DESCRIPTION

- 84165 Protein; electrophoretic fractionation and quantitation, serum
- 84166 electrophoretic fractionation and quantitation, other fluids with concentration (e.g., urine, CSF)
- 84202 Protoporphyrin, RBC; quantitative
- 84207 Pyridoxal phosphate (Vitamin B-6)
- 84220 Pyruvate kinase
- 84233 Receptor assay; estrogen
- 84234 progesterone
- 84275 Sialic acid
- 84295 Sodium; serum, plasma or whole blood (see Rule 11)
- 84300 urine (see Rule 11)
- 84302 other source

(For Somatotropin, see 83003)

- 84305 Somatomedin
- 84375 Sugars, chromatographic, TLC or paper chromatography
- 84376 Sugars (mono-,di-, and oligosaccharides); single qualitative, each specimen
- 84377 multiple qualitative, each specimen
- single quantitative, each specimen
- 84379 multiple quantitative, each specimen
- 84402 Testosterone; free
- 84403 total
- 84425 Thiamine (Vitamin B-1)
- 84436 Thyroxine; total
- 84439 free
- 84442 Thyroxine binding globulin (TBG)
- 84443 Thyroid stimulating hormone (TSH)
- 84446 Tocopherol alpha (Vitamin E)
- 84449 Transcortin (cortisol binding globulin)
- 84450 Transferase; aspartate amino (AST) (SGOT) (see Rule 11)
- alanine amino (ALT) (SGPT) (see Rule 11)
- 84466 Transferrin
- 84478 Triglycerides (see Rule 11)
- 84479 Thyroid hormone (T3 or T4) uptake (with or without) thyroid hormone binding ratio (THBR)
- 84480 Triiodothyronine T3; total (TT-3)
- 84481 free
- 84482 reverse
- 84484 Troponin, quantitative
- 84510 Tyrosine
- 84512 Troponin, qualitative
- 84520 Urea nitrogen; quantitative (see Rule 11)
- 84540 urine (see Rule 11)

DESCRIPTION

- 84550 Uric acid; blood (see Rule 11)
- other source (see Rule 11)
- 84585 Vanillylmandelic acid (VMA), urine
- 84588 Vasopressin (antidiuretic hormone, ADH)
- 84590 Vitamin A
- 84591 Vitamin, not otherwise specified
- 84597 Vitamin K
- 84620 Xylose absorption test, blood and/or urine
- 84630 Zinc
- 84681 C-peptide
- 84702 Gonadotropin, chorionic (hCG); quantitative (see Rules 9 and 15)
- 84703 qualitative (see Rule 9)
- 84704 free beta chain
- 84999 Unlisted chemistry/genetic testing procedure (see Rule 3)

(Reimbursement is limited to the listed analytes for the purpose of providing information for diagnosis or monitoring of genetic disease or carrier state. Clinical applications other than genetic testing are subject to a coverability determination for unlisted procedures.)

Acetylglucosamidase, Alpha N-Acid Maltase Acyl-CoA Dehydrogenase, Medium Chain Short Chain Adenosine deaminase Adenylate kinase Aldolase Arginosuccinase Arylsulfatase A,B and/or C ATPase Citrate Synthase Cytochrome Oxidase Dihydropteridine Reductase Dystrophin Enolase Fatty Acids, Long Chain Fucosidase, Alpha and/or Beta Fumarase Galactocerebrosidase, Beta Galactose -4- Sulfatase Galactose -6- Sulfatase Galactosidase, Alpha and/or Beta Glucocerebrosidase, Beta Glucuronidase, Beta Glyceraldehyde -3-P-Dehydrogenase Glycerophosphate Dehydrogenase, Alpha Hexosaminidase. A Iduronidase, alpha Iduronosulfatase Mannosidase, Alpha and/or Beta Myoadenylate Deaminase NADH Cytochrome C Reductase NADH Dehydrogenase

Neuraminidase Nucleoside Phosphorylase **Ornithine Carbamyl** Transferase (OCT) Phosphofructokinase Phosphoglucomutase, Isoenzymes Phosphoglycerate Kinase Phosphoglycerate Mutase Phosphorylase Phosphorylase B Kinase Phytanic acid Pyruvate Decarboxylase Sphingomyelinase Succinate Cytochrome C Reductase Succinate Dehydrogenase Sulfaminidase Triose phosphate Isomerase

DESCRIPTION

HEMATOLOGY and COAGULATION

- 85002 Bleeding time
- 85004 Blood count; automated differential WBC count
- 85007 blood smear, microscopic examination with manual differential WBC count (includes RBC morphology and platelet estimation)
- 85013 spun microhematocrit
- 85014 hematocrit
- 85018 hemoglobin (Hgb)
- 85025 complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count), and automated differential WBC count
- 85027 complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count)
- 85032 manual cell count (erythrocyte, leukocyte, or platelet) each
- red blood cell (RBC), automated
- 85044 reticulocyte, manual
- 85045 reticulocyte, automated
- 85046 reticulocytes, automated, including one or more cellular parameters (e.g. reticulocyte hemoglobin content (CHr), immature reticulocyte volume (MRV), RNA content), direct measurement
- 85048 leukocyte (WBC), automated
- 85049 platelet, automated
- 85055 Reticulated platelet assay
- 85060 Blood smear, peripheral, (including) interpretation by physician with written report
- 85097 Bone marrow; smear interpretation

(For bone marrow biopsy or cell block interpretation, use 88305)

- 85210 Clotting; factor II, prothrombin, specific
- 85220 factor V (AcG or proaccelerin), labile factor
- 85230 factor VII (proconvertin, stable factor)
- factor VIII (AHG), one stage
- 85244 factor VIII related antigen
- 85245 factor VIII, VW factor, ristocetin cofactor
- 85246 factor VIII, VW factor antigen
- 85247 factor VIII, Von Willebrand factor, multimetric analysis
- 85250 factor IX (PTC or Christmas)
- 85260 factor X (Stuart-Prower)
- 85270 factor XI (PTA)
- 85280 factor XII (Hageman)
- 85290 factor XIII (fibrin stabilizing)
- 85291 factor XIII (fibrin stabilizing), screen solubility
- 85292 prekallikrein assay (Fletcher factor assay)
- high molecular weight kininogen assay (Fitzgerald factor assay)

DESCRIPTION

Clotting inhibitors or anticoagulants; antithrombin III, activity 85300 85301 antithrombin III, antigen assay protein C, antigen 85302 protein C, activity 85303 protein S, total 85305 85306 protein S, free Activated Protein C (APC) resistance assay 85307 Factor inhibitor test 85335 85337 Thrombomodulin 85347 Coagulation time; activated 85348 other methods 85360 Euglobulin lysis Fibrin(ogen) degradation (split) products (FDP) (FSP); agglutination slide, 85362 semiquantitative 85366 paracoagulation 85370 quantitative Fibrin degradation products, D-dimer; qualitative or semiguantitative 85378 85379 quantitative 85380 ultrasensitive (e.g., for evaluation for venous thromboembolism), qualitative or semiguantitative Fibrinogen; activity 85384 85385 antigen 85397 Coagulation and fibrinolysis, functional activity, not otherwise specified (eq. ADAMTS-13), each analyte Heinz bodies; direct 85441 85445 induced, acetyl phenylhydrazine (For hemoglobin, see 83020-83051) 85460 Hemoglobin or RBCs, fetal, for fetomaternal hemorrhage; differential lysis (Kleihauer-Betke) 85461 rosette 85475 Hemolysin, acid Heparin assay 85520 85536 Iron stain, peripheral blood (For iron stains on bone marrow smears, use code 88313) (For Leder (esterase) stain, use 88319) Leukocyte alkaline phosphatase with count 85540 (For LE factor by latex, use 86235; for lupus anticoagulant, see 85613, 85705) Muramidase 85549 85555 Osmotic fragility, RBC; unincubated 85557 incubated

DESCRIPTION

- 85576 Platelet; aggregation (in vitro), each agent
- 85610 Prothrombin time
- 85612 Russell viper venom time (includes venom); undiluted
- 85613 diluted
- 85635 Reptilase test
- 85651 Sedimentation rate, erythrocyte; non-automated
- 85652 automated
- 85670 Thrombin time; plasma
- 85705 Thromboplastin inhibition; tissue
- 85730 Thromboplastin time, partial (PTT); plasma or whole blood
- substitution, plasma fractions, each
- 85810 Viscosity

IMMUNOLOGY

Immunologic tests for antigen or antibody should be reported using the most specific code available. For infectious agent antibody or antigen tests, see codes 86602 – 86793 and the cross-references located in that coding range. See Rules 6 and 10. For antigen identification in solid tissue, see 88342-88347 in Surgical Pathology.

- 86038 Antinuclear antibodies (ANA);
- 86039 titer
- 86060 Antistreptolysin 0; titer
- 86063 screen
- 86140 C-reactive protein;
- high sensitivity (hsCRP)
- 86146 Beta 2 Glycoprotein 1 antibody, each
- 86147 Cardiolipin (phospholipid) antibody, each Ig class
- 86148 Anti-phosphatidylserine (phospholipid) antibody
- 86157 Cold agglutinin; titer
- 86160 Complement; antigen, each component
- 86161 functional activity, each component
- total hemolytic (CH50)
- 86215 Deoxyribonuclease, antibody
- 86225 Deoxyribonucleic acid (DNA) antibody; native or double stranded
- 86235 Extractable nuclear antigen, antibody to, any method (e.g., nRNP, SS-A, SS-B, Sm, RNP, Scl70, J01), each antibody
- 86255 Fluorescent noninfectious agent antibody; screen, each antibody, (not elsewhere specified) (see Rule 10)
- titer, each antibody (not elsewhere specified) (see Rule 10)
- 86294 Immunoassay for tumor antigen, qualitative or semiquantitative (e.g., bladder tumor antigen) (see Rule 15)
- 86300 Immunoassay for tumor antigen, quantitative; CA 15-3 (27.29) (see Rule 15)
- 86301 CA 19-9 (see Rule 15)
- 86304 CA 125 (see Rule 15)

<u>CODE</u>

DESCRIPTION

86305 86308 86309 86316	 Human epididymis protein 4 (HE4) Heterophile antibodies; screening titer Immunoassay for tumor antigen; other antigen, quantitative, (e.g., CA 50,72-4, 549), each (not elsewhere specified) (see Rule 15)
	(For measurement of serum HER-2/neu oncoprotein, see 83950)
	(For quantitative immunoassay of infectious agent antibody, use the organism specific codes 86602 et seq.)
86318	Immunoassay for infectious agent antibody, qualitative or semiquantitative, single step method (not elsewhere specified) (e.g., reagent strip)
	(For Streptococcus screen, see 86063 or 87880)
86320 86325 86329	Immunoelectrophoresis; serum other fluids (e.g., urine, cerebrospinal fluid) with concentration Immunodiffusion; not elsewhere specified
	(For quantitation of antigenic complement, e.g., C2 or C3, use 86160)
86334 86335 86336 86340 86340 86341 86355 86355 86357 86359 86360 86361	Immunofixation electrophoresis; serum other fluids with concentration (e.g., urine, CSF) Inhibin A Insulin antibodies Intrinsic factor antibodies Islet cell antibody (see Rule 19) B cells, total count (see Rule 18) Natural killer (NK) cells, total count (see Rule 18) T cells; total count absolute CD4 and CD8 count, including ratio absolute CD4 count
	(For T-cell immunophenotyping, see Rule 18)
86367 86376 86382 86403 86430 86431 86480 86592 86593	Stem cells (e.g., CD34), total count (see Rule 18) Microsomal antibodies (e.g., thyroid or liver-kidney), each Neutralization test, viral Particle agglutination; screen, each antibody Rheumatoid factor; qualitative quantitative Tuberculosis test, cell mediated immunity measurement of gamma interferon antigen response Syphilis test, non-treponemal antibody; qualitative (e.g., VDRL, RPR, ART) quantitative (includes screen and titer)
	(For infectious agent antibody or antigen tests not listed by name, see Rule 10 A, B; for maximum reimbursable amounts for two or more infectious agent tests, see Rule 6C.)

<u>CODE</u>

DESCRIPTION

86602	Antibody; actinomyces
86603	adenovirus
86606	Aspergillus
86609	bacterium, not elsewhere specified
86611	Bartonella
86612	Blastomyces
86615	Bordetella
86617	Borrelia burgdorferi (Lyme disease) confirmatory test (e.g., Western blot
00017	or immunoblot)
86618	Borrelia burgdorferi (Lyme disease)
86619	Borrelia (relapsing fever)
86622	Brucella
86625	Campylobacter
86631	Chlamydia
86632	Chlamydia, IgM
86635 86638	Coccidioides
86641	Coxiella brunetii (Q fever)
	Cryptococcus
86644	cytomegalovirus (CMV)
86645	cytomegalovirus (CMV), IgM
86651	encephalitis, California (La Crosse)
86652	encephalitis, Eastern equine
86653	encephalitis, St. Louis
86654	encephalitis, Western equine
86658	enterovirus (e.g., coxsackie, echo, polio)
86663	Epstein-Barr (EB) virus, early antigen (EA)
86664	Epstein-Barr (EB) virus, nuclear antigen (EBNA)
86665	Epstein-Barr (EB) virus, viral capsid (VCA)
86666	Ehrlichia
86668	Francisella tularensis
86671	fungus, not elsewhere specified
86674	Giardia lamblia
86677	Helicobacter pylori
86682	helminth, not elsewhere specified
	(For fecal hemoglobulin detection by immunoassay, use 82274)
86684	Hemophilus influenza
86687	HTLV-I
86689	HTLV or HIV antibody, confirmatory test (e.g., Western Blot)
86692	hepatitis, delta agent
86696	herpes simplex, type 2
86698	histoplasma
86701	HIV-1
00700	

86702 HIV-2

DESCRIPTION

86703 HIV-1 and HIV-2, single assay

(For maximum reimbursable amounts for hepatitis tests performed in combination, see Rule 6C)

86704 Hepatitis B core antibody (HBcAb), total

- 86705 IgM antibody
- 86706 Hepatitis B surface antibody (HBsAb)
- 86707 Hepatitis Be antibody (HBeAb)
- 86708 Hepatitis A antibody (HAAb), total
- 86709 IgM antibody
- 86710 Antibody; influenza virus
- 86713 Legionella
- 86717 Leishmania
- 86720 Leptospira
- 86723 Listeria monocytogenes
- 86727 lymphocytic choriomeningitis
- 86729 lymphogranuloma venereum
- 86735 mumps
- 86738 mycoplasma

(For Neisseria gonorrhoeae antigen, see 87590 or 87591)

- 86741 Neisseria meningitidis
- 86744 Nocardia
- 86747 parvovirus
- 86750 Plasmodium (malaria)
- 86753 protozoa, not elsewhere specified
- 86756 respiratory syncytial virus
- 86757 Rickettsia
- 86759 rotavirus
- 86762 rubella
- 86765 rubeola
- 86768 Salmonella
- 86771 Shigella

(For Streptococcus direct screen, see 87880)

- 86777 Toxoplasma
- 86778 Toxoplasma, IgM
- 86780 Treponema pallidum

(For syphilis testing by non-treponemal antibody analysis, see 86592, 86593)

- 86784 Trichinella
- 86787 varicella-zoster
- 86788 West Nile virus, IgM
- 86789 West Nile virus

CODE DESCRIPTION

- 86790 virus, not elsewhere specified
- 86793 Yersinia
- 86800 Thyroglobulin antibody
- 86803 Hepatitis C antibody;
- 86804 confirmatory test (e.g., immunoblot)

(For thyroid autoantibodies, use 86376)

TRANSFUSION MEDICINE

- 86850 Antibody screen, RBC, each serum technique
- 86860 Antibody elution (RBC), each elution
- 86870 Antibody identification, RBC antibodies, each panel for each serum technique
- 86880 Antihuman globulin test (Coombs test); direct, each antiserum
- 86900 Blood typing; ABO
- 86901 Rh (D)
- 86905 RBC antigens, other than ABO or Rh (D), each
- 86940 Hemolysins and agglutinins; auto, screen, each
- 86941 incubated

MICROBIOLOGY

- 87015 Concentration (any type), for infectious agents
- 87040 Culture, bacterial; blood, aerobic, with isolation and presumptive identification of isolates (includes anaerobic culture, if appropriate)
- 87045 stool, aerobic, with isolation and preliminary examination (e.g., KIA, LIA), Salmonella and Shigella species
- 87046 stool, aerobic, additional pathogens, isolation and presumptive identification of isolates, each plate
- 87070 any other source except urine, blood or stool, aerobic, with isolation and presumptive identification of isolates

(For urine, use 87086 - 87088)

- 87075 any source, except blood, anaerobic with isolation and presumptive identification of isolates
- 87076 anaerobic isolate, additional methods required for definitive identification, each isolate
- 87077 aerobic isolate, additional methods required for definitive identification, each isolate
- 87081 Culture, presumptive, pathogenic organisms, screening only
- 87086 Culture, bacterial; quantitative colony count, urine
- 87088 with isolation and presumptive identification of each isolates, urine

Culture, fungi (mold or yeast) isolation, with presumptive identification of

CODE

87101

isolates; skin, hair, or nail other source (except blood) 87102 87103 blood 87106 Culture, fungi, definitive identification, each organism; yeast (Use in addition to codes 87101, 87102, or 87103 when appropriate) 87107 mold 87109 Culture, mycoplasma, any source Culture, chlamydia, any source 87110 Culture, tubercle or other acid-fast bacilli (e.g., TB, AFB, mycobacteria) any 87116 source, with isolation and presumptive identification of isolates Culture, mycobacterial, definitive identification, each isolate 87118 Dark field examination, any source (e.g., penile, vaginal, oral, skin); includes 87164 specimen collection 87166 without collection 87169 Macroscopic examination; parasite Pinworm exam (e.g., cellophane tape prep) 87172 Ova and parasites, direct smears, concentration and identification 87177 87181 Susceptibility studies, antimicrobial agent; agar dilution method, per agent (e.g., antibiotic gradient strip) 87184 disk method, per plate (12 or fewer agents) enzyme detection (e.g., beta lactamase), per enzyme 87185 microdilution or agar dilution (minimum inhibitory concentration (MIC) or 87186 breakpoint), each multi-antimicrobial, per plate macrobroth dilution method, each agent 87188 mycobacteria, proportion method, each agent 87190 87205 Smear, primary source with interpretation; Gram or Giemsa stain for bacteria, fungi or cell types 87206 fluorescent and/or acid fast stain for bacteria, fungi, parasites, viruses or cell types special stain for inclusion bodies or parasites (e.g., malaria, coccidia, 87207 microsporidia, trypanosomes, herpes viruses) 87209 complex special stain (e.g., trichrome, iron hemotoxylin) for ova and parasites 87210 wet mount for infectious agents (e.g., saline, India ink, KOH preps) (Does not include KOH on skin, hair or nails) Toxin or antitoxin assay, tissue culture (e.g., Clostridium difficile toxin) 87230 Virus isolation; inoculation of embryonated eggs, or small animal, includes 87250 observation and dissection 87252 tissue culture inoculation, observation, and presumptive identification by cvtopathic effect tissue culture, additional studies or definitive identification (e.g., 87253 hemabsorption, neutralization, immunofluorescence stain), each isolate Version 2010 - 1 (06-01-10)

DESCRIPTION

- 87254 centrifuge enhanced (shell vial) technique, includes identification with immunofluorescence stain, each virus
- 87255 including identification by non-immunologic method, other than by cytopathic effect (e.g., virus specific enzymatic activity)
- 87260 Infectious agent antigen detection by immunofluorescent technique; adenovirus
- 87265 Bordetella pertussis/parapertussis
- 87269 giardia
- 87270 Chlamydia trachomatis
- 87271 Cytomegalovirus, direct fluorescent antibody (DFA)
- 87272 cryptosporidium
- 87273 Herpes simplex virus type 2
- 87274 Herpes simplex virus type 1
- 87275 influenza B virus
- 87276 influenza A virus

(For rapid flu test, use 87804)

- 87278 Legionella pneumophila
- 87279 Parainfluenza virus, each type
- 87280 respiratory syncytial virus
- 87281 Pneumocystis carinii
- 87290 Varicella zoster virus
- not otherwise specified, each organism (see Rule 10B)
- 87301 Infectious agent antigen detection by enzyme immunoassay technique, qualitative or semiquantitative, multiple step method; adenovirus enteric types 40/41
- 87305 Aspergillus
- 87320 Chlamydia trachomatis
- 87324 Clostridium difficile toxin(s)
- 87327 Cryptococcus neoformans
- 87328 cryptosporidium
- 87329 giardia
- 87332 cytomegalovirus
- 87335 Escherichia coli 0157
- 87336 Entamoeba histolytica dispar group
- 87337 Entamoeba histolytica group
- 87338 Helicobacter pylori, stool
- hepatitis B surface antigen (HBsAg)
- 87341 hepatitis B surface antigen (HBsAg) neutralization
- 87350 hepatitis Be antigen (HBeAg)
- 87380 hepatitis, delta agent
- 87385 Histoplasma capsulatum
- 87390 HIV-1 (e.g., P24 antigen)
- 87420 respiratory syncytial virus
- 87425 rotavirus

CODE DESCRIPTION

- 87427 Shiga-like toxin
- 87430 Streptococcus, group A

(For streptococcus screen, see 87880)

- 87449 Infectious agent antigen detection by enzyme immunoassay technique qualitative or semiquantitative; multiple step method, not otherwise specified, each organism
- single step method, not otherwise specified, each organism
- 87476 Infectious agent detection by nucleic acid (DNA or RNA); Borrelia burgdorferi, amplified probe technique
- 87480 Candida species, direct probe technique
- 87486 Chlamydia pneumoniae, amplified probe technique
- 87490 Chlamydia trachomatis, direct probe technique
- 87491 Chlamydia trachomatis, amplified probe technique
- 87495 cytomegalovirus, direct probe technique
- 87498 enterovirus, amplified probe technique
- 87500 vancomycin resistance (eg, enterococcus species van a, van b), amplified probe technique
- 87510 Gardnerella vaginalis, direct probe technique
- 87516 hepatitis B virus, amplified probe technique
- 87521 hepatitis C, amplified probe technique
- 87522 hepatitis C, quantification
- 87535 HIV-1, amplified probe technique
- 87536 HIV-1, quantification
- 87551 Mycobacteria species, amplified probe technique
- 87556 Mycobacteria tuberculosis, amplified probe technique
- 87561 Mycobacteria avium-intracellulare, amplified probe technique
- 87581 Mycoplasma pneumoniae, amplified probe technique
- 87590 Neisseria gonorrhoeae, direct probe technique
- 87591 Neisseria gonorrhoeae, amplified probe technique
- 87620 papillomavirus, human, direct probe technique
- 87621 papillomavirus, human, amplified probe technique
- 87640 Staphylococcus aureus, amplified probe technique
- 87641 Staphylococcus aureus, methicillin resistant, amplified probe technique (includes staphylococcus aureus identification)
- 87650 Streptococcus, group A, direct probe technique
- 87653 Streptococcus, group B, amplified probe technique
- 87660 Trichomonas vaginalis, direct probe technique
- 87797 Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; direct probe technique, each organism
- 87798 amplified probe technique, each organism
- 87800 Infectious agent detection by nucleic acid(DNA or RNA), multiple organisms; direct probe(s) technique
- 87801 amplified probe(s) technique

DESCRIPTION

- 87803 Infectious agent antigen detection by immunoassay with direct optical observation; Clostridium difficile toxin A
- 87804 influenza
- 87807 respiratory syncytial virus
- 87808 Trichomonas vaginalis
- 87809 adenovirus
- 87880 Infectious agent detection by immunoassay with direct optical observation; Streptococcus, group A
- 87899 not otherwise specified
- 87900 Infectious agent drug susceptibility phenotype prediction using regularly updated genotypic bioinformatics
- 87901 Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV 1, reverse transcriptase and protease
- 87902 Hepatitis C virus
- 87903 Infectious agent phenotype analysis by nucleic acid (DNA or RNA) with drug resistance tissue culture analysis, HIV 1; first through 10 drugs tested
- 87904 each additional drug tested (List separately in addition to primary procedure)

CYTOPATHOLOGY

- 88104 Cytopathology, fluids, washings or brushings, except cervical or vaginal; smears with interpretation
- simple filter method with interpretation
- 88107 smears and simple filter preparation with interpretation
- 88108 Cytopathology, concentration technique, smears and interpretation (e.g., Saccomanno technique)
- 88112 Cytopathology, selective cellular enhancement technique with interpretation (e.g., liquid based slide preparation method), except cervical or vaginal (Do not report 88112 with 88108)
- 88141 Cytopathology, cervical or vaginal (any reporting system); requiring interpretation by physician
 (List separately in addition to code for technical service)
- 88142 Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; manual screening under
 - physician supervision
- 88143 with manual screening and rescreening under physician supervision
- 88147 Cytopathology smears, cervical or vaginal; screening by automated system under physician supervision
- 88148 screening by automated system with manual re-screening under physician supervision
- 88150 Cytopathology, slides, cervical or vaginal; manual screening under physician supervision

DESCRIPTION

- 88153 with manual screening and rescreening under physician supervision
- 88160 Cytopathology, smears, any other source (specify); screening and interpretation 88161 preparation, screening and interpretation
- 88162 extended study involving over 5 slides and/or multiple stains
- 88164 Cytopathology, slides, cervical or vaginal (the Bethesda System); manual screening under physician supervision
- 88165 with manual screening and rescreening under physician supervision
- 88173 Cytopathology, evaluation of fine needle aspirate; interpretation and report
- 88174 Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; screening by automated system, under physician supervision
- 88175 with screening by automated system and manual rescreening or review under physician supervision

(See Rule 22 for instrumented PAP screening definitions)

- 88184 Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; first marker
- 88185 each additional marker (List separately in addition to code for first marker)
- 88187 Flow cytometry, interpretation; 2 to 8 markers
- 88188 9 to 15 markers
- 88189 16 or more markers

CYTOGENETIC STUDIES

Cytogenetic studies procedure codes 88245, 88267 and 88269 must be billed in combination with procedure code 88280 to report a 2-karyotype chromosome analysis as described in the quality control standards for cytogenetic licensure.

(For acetylcholinesterase, use 82013)

(For alpha-fetoprotein, serum or amniotic fluid, use 82105, 82106)

- 88230 Tissue culture for non-neoplastic disorders; lymphocyte
- skin or other solid tissue biopsy
- 88235 amniotic fluid or chorionic villus cells
- 88237 Tissue culture for neoplastic disorders; bone marrow, blood cells
- solid tumor
- 88245 Chromosome analysis for breakage syndromes; baseline Sister Chromatid Exchange (SCE), 20-25 cells
- 88248 baseline breakage, score 50-100 cells, count 20 cells, 2 karyotypes (e.g., for ataxia telangiectasia, Fanconi anemia, fragile X)
- 88249 score 100 cells, clastogen stress (e.g., diepoxybutane, mitomycin C, ionizing radiation, UV radiation)
- 88262 Chromosome analysis; count 15-20 cells, 2 karyotypes, with banding
- count 45 cells for mosaicism, 2 karyotypes, with banding

CODE DESCRIPTION

- 88267 Chromosome analysis, amniotic fluid or chorionic villus, count 15 cells, 1 karyotype, with banding
- 88269 Chromosome analysis, in situ for amniotic fluid cells, count cells from 6-12 colonies, 1 karyotype, with banding
- 88271 Molecular cytogenetics; DNA probe, each (e.g. FISH)
- 88272 chromosomal in situ hybridization, analyze 3-5 cells (e.g. for derivatives and markers)
- 88273 chromosomal in situ hybridization, analyze 10-30 cells (e.g. for microdeletions)
- interphase in situ hybridization, analyze 25-99 cells
- 88275 interphase in situ hybridization, analyze 100-300 cells
- 88280 Chromosome analysis; additional karyotypes, each study (Use in addition to code 88267, 88269)
- 88285 additional cells counted, each study (Use in addition to code 88269)
- 88291 Cytogenetics and molecular cytogenetics, interpretation and report

SURGICAL PATHOLOGY

Surgical pathology procedure codes are reimbursable per specimen. A specimen is defined as tissue or tissues that is (are) submitted for individual and separate attention, requiring individual examination and pathologic diagnosis. Any unlisted specimen should be assigned to the code which most closely reflects the work involved when compared to other specimens assigned to that code.

88302 LEVEL II - Surgical pathology, gross and microscopic examination

Appendix, Incidental Fallopian Tube, Sterilization Fingers/Toes, Amputation, Traumatic Foreskin, Newborn Hernia Sac, Any Location Hydrocele Sac Nerve Skin, Plastic Repair Sympathetic Ganglion Testis, Castration Vaginal Mucosa, Incidental Vas Deferens, Sterilization

88304 LEVEL III - Surgical pathology, gross and microscopic examination

Abortion, Induced Abscess Aneurysm - Arterial/Ventricular Anus, Tag Appendix, Other than Incidental Artery, Atheromatous Plaque Bartholin's Gland Cyst Bone Fragment(s), Other than Pathologic Fracture Bursa/Synovial Cyst **Carpal Tunnel Tissue** Cartilage, Shavings Cholesteatoma Colon, Colostomy Stoma Conjunctiva - Biopsy/Pterygium Cornea

Diverticulum -Esophagus/Small Intestine Dupuytren's Contracture Tissue Femoral Head, Other than Fracture Fissure/Fistula Foreskin,Other than Newborn Gallbladder Ganglion Cyst Hematoma Hemorrhoids Hydatid of Morgagni Intervertebral Disc Joint, Loose Body Meniscus Mucocele, Salivary

Neuroma-Morton's/Traumatic Pilonidal Cyst/Sinus Polyps, Inflammatory -Nasal/Sinusoidal Skin - Cyst/Tag/Debridement Soft Tissue, Debridement Soft Tissue, Lipoma Spermatocele Tendon/Tendon Sheath **Testicular Appendage** Thrombus or Embolus Tonsil and/or Adenoids Varicocele Vas Deferens, Other than Sterilization Vein, Varicosity

DESCRIPTION

88305 LEVEL IV - Surgical pathology, gross and microscopic examination

Abortion - Spontaneous/ Missed Artery, Biopsy Bone Marrow, Biopsy Bone. Exostosis Brain/Meninges, Other than For Tumor Resection Breast, Biopsy, Not Requiring Microscopic Evaluation of Surgical Margins Breast. Reduction Mammoplastv Bronchus, Biopsy Cell Block, Any Source Cervix, Biopsy Colon, Biopsy Duodenum, Biopsy Endocervix, Curettings/Biopsy Endometrium Curettings/Biopsy Esophagus, Biopsy Extremity, Amputation, Traumatic Fallopian Tube, Biopsy Fallopian Tube, Ectopic Pregnancy Femoral Head, Fracture Finger/Toes, Amputation, Non-traumatic Gingiva/Oral Mucosa, Biopsy

Heart Valve Joint, Resection Kidney, Biopsy Larynx, Biopsy Leiomyoma (s), Uterine Myomectomy without Uterus Lip, Biopsy/Wedge Resection Lung, Transbronchial Biopsy Lymph Node, Biopsy Muscle, Biopsy Nasal Mucosa, Biopsv Nasopharynx/Oropharynx, Biopsy Nerve, Biopsy Odontogenic/Dental Cyst Omentum, Biopsy Ovary with or without Tube, Non-neoplastic Ovary, Biopsy/ Wedge Resection Parathyroid Gland Peritoneum, Biopsy Pituitary Tumor Placenta, Other than Third Trimester Pleura/Pericardium-Biopsy/Tissue Polyp, Cervical/Endometrial Polyp, Colorectal

Polyp, Stomach/Small Intestine Prostate, Needle Biopsy Prostate, TUR Salivary Gland, Biopsy Sinus, Paranasal Biopsv Skin, Other than Cyst/Tag/ Debridement/Plastic Repair Small Intestine, Biopsy Soft Tissue, Other than Tumor/Mass/Lipoma/Debridement Spleen Stomach, Biopsy Synovium Testis, Other than Tumor/ **Biopsy/Castration** Thyroglossal Duct/Brachial Cleft Cyst Tongue, Biopsy Tonsil, Biopsy Trachea, Biopsy Ureter, Biopsy Urethra, Biopsy Urinary Bladder, Biopsy Uterus, with or without Tubes & Ovaries. for Prolapse Vagina, Biopsy Vulva/Labia, Biopsy

88307 LEVEL V - Surgical pathology, gross and microscopic examination

Adrenal, Resection Bone - Biopsy/Curettings Bone Fragment(s), Pathologic Fracture Brain, Biopsy Brain/Meninges, Tumor Resection Breast, Excision of Lesion, **Requiring Microscopic Evaluation of Surgical** Margins Breast, Mastectomy -Partial/Simple Cervix, Conization Colon, Segmental Resection, Other than for Tumor Extremity, Amputation, Non-traumatic Eye, Enucleation

Kidney, Partial/Total Nephrectomy Larynx, Partial/Total Resection Liver, Biopsy -Needle/Wedge Liver. Partial Resection Lung, Wedge Biopsy Lymph Nodes, Regional Resection Mediastinum, Mass Myocardium, Biopsy Odontogenic Tumor Ovary with or without Tube, Neoplastic Pancreas, Biopsy Placenta, Third Trimester Prostate, Except Radical Resection

Salivary Gland Sentinel Lymph Node Small Intestine, Resection, Other than for Tumor Soft Tissue Mass (except Lipoma) - Biopsy/Simple Excision Stomach - Subtotal/Total Resection, Other than for Tumor Testis, Biopsy Thymus, Tumor Thyroid, Total/Lobe Ureter, Resection Urinary Bladder, TUR Uterus, with or without Tubes and Ovaries, Other than Neoplastic/Prolapse

DESCRIPTION

88309 LEVEL VI - Surgical pathology, gross and microscopic examination

Bone Resection Breast, Mastectomy - with Regional Lymph Nodes Colon, Segmental Resection for Tumor Colon, Total Resection Esophagus, Partial/ Total Resection Extremity, Disarticulation Fetus, with Dissection Larynx, Partial/Total Resection - with Regional Lung - Total/Lobe/ Segment Resection Pancreas - Total/Subtotal Resection Prostate, Radical Resection Small Intestine, Resection for Tumor Soft Tissue Tumor, Extensive Resection Stomach - Subtotal/Total Resection, Tumor ..Lymph Nodes

- Testis, Tumor Tongue/Tonsil -Resection for Tumor Urinary Bladder, Partial/ Total Resection Uterus, with or without Tubes & Ovaries, Neoplastic Vulva - Total/ Subtotal Resection
- 88312 Special stains (List separately in addition to code for primary service); Group I for microorganisms (e.g., Gridley, acid fast, methenamine silver), including interpretation and report, each
- 88313 Group II, all other (e.g., iron, trichrome), except immunocytochemistry and immunoperoxidase stains, including interpretation and report, each
- 88319 Determinative histochemistry or cytochemistry to identify enzyme constituents, each
- 88342 Immunohistochemistry (including tissue immunoperoxidase), each antibody

(For immunophenotyping, see Rule 18)

- 88346 Immunofluorescent study, each antibody; direct method
- indirect method
- 88360 Morphometric analysis, tumor immunohistochemistry (e.g., Her-2/Neu, estrogen receptor/progesterone receptor), quantitative or semiquantitative, each antibody; manual
- using computer assisted technology (computer generated)

(Do not report 88360 or 88361 with 88342 unless each procedure is for a different antibody)

(When semi-thin plastic-embedded sections are performed in conjunction with morphometric analysis, only the morphometric analysis should be reported; if performed as an independent procedure, see codes 88302-88309 for surgical pathology)

OTHER PROCEDURES

- 89050 Cell count, miscellaneous body fluids (e.g., cerebrospinal fluid, joint fluid), except blood;
- 89051 with differential count
- 89055 Leukocyte assessment, fecal, qualitative or semiquantitative
- 89060 Crystal identification by light microscopy with or without polarizing lens analysis, tissue or any body fluid (except urine)
- 89190 Nasal smear for eosinophils

<u>CODE</u>

DESCRIPTION

- 89230 Sweat collection by iontophoresis (includes analysis)
- 89321 Semen analysis; sperm presence and motility of sperm, if performed
- 91065 Breath hydrogen test (e.g., for detection of lactase deficiency, fructose intolerance, bacterial overgrowth, or oro-cecal gastrointestinal transit)
- P9604 Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge (Limited to home bound phlebotomy; see Rule 23)